Press Releases

BIOMS MEDICAL ANNOUNCES LEAD INVESTIGATOR IN SWEDEN FOR MS TRIAL

Edmonton, Alberta, September 12, 2005 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), is pleased to announce Dr. Tomas Olsson as the lead investigator in Sweden for the Company’s multi-national pivotal Phase II/III clinical trial of its lead drug, MBP8298, for the treatment of secondary progressive multiple sclerosis.

Dr. Olsson is Head of CNS research, Professor of Molecular Medicine, and Senior Staff Physician of Neurology at the Karolinska Hospital, Stockholm, Sweden.

“Dr. Olsson is one of the leading researchers of multiple sclerosis in the world. The Company is very fortunate to have his expertise and knowledge for our trial in Sweden,” said Kevin Giese, President of BioMS Medical. “We anticipate that patient enrollment will commence very shortly in that country.”

Dr. Olsson is a member of the Nobel assembly, as well as member of editorial boards for scientific journals in neurology and grants reviewing committees. He was Chairman for the Swedish expert committee for MS from 1997-2002 and is a member of the board of the Swedish MS society. Dr. Olsson is also a member of both the international MS societies and the international scientific board of the European committee for the treatment of MS. Dr. Olsson is co-founder of the European school of Neuroimmunology, and is a member of its board. Dr. Olsson has been the principal investigator in several phase I, II and III trials in MS.

BioMS Medical’s pivotal Phase II/III trial, which is currently enrolling patients in Canada and the U.K. is a double-blind, placebo-controlled study involving up to 553 patients

This press release may contain forward-looking statements, which reflect the Corporation’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Corporation’s ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide (MBP8298) will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.